RYZ-101-301 A Phase Ib/3 global, randomized, controlled, open-label trial comparing treatment with Actinium Ac225 dotatate (RYZ101) to standard of care therapy in subjects with inoperable, advanced, somatostatin receptor expressing (SSTR+) gastroentero pancreatic neuroendocrine tumors that have progressed following prior treatment with 177Lu-Dotatate or 177Lu-DOTATOC Ac225 dotatate vs SOC
- Phase I
- Trial Category: Gastrointestinal, Other Solid Tumor
Contact(s)
Mary Beth Wilwerding, RN Admin@NEcancertrials.com
Location(s)
Available at Nebraska Cancer Specialists, Omaha, NE location
Interested in More Information?
Please fill out the form below. Someone will get back to you as soon as possible.
"*" indicates required fields